ML115 is a selective antagonist of the sphingosine-1-phosphate receptor 3 (S1P3), primarily utilized in medicinal chemistry and drug development. It inhibits S1P3-mediated signaling, which is valuable for studying biochemical pathways involved in inflammation, cardiovascular function, and immune responses. Researchers employ ML115 to investigate potential therapeutic effects in conditions such as cancer, inflammatory diseases, pulmonary hypertension, and neurological disorders including multiple sclerosis. Its specificity allows exploration of targeted therapies modulating S1P signaling. Additionally, ML115 is used in preclinical studies to evaluate efficacy, safety, pharmacokinetics, and potential off-target effects, aiding the development of novel pharmaceuticals.